Lead Product(s) : Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules Strengthens ADHD Portfolio with FDA Approval for Lisdexamfetamine Dimesylate
Details : FDA approved Lisdexamfetamine Dimesylate Capsules, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.
Product Name : Vyvanse-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 30, 2025
Lead Product(s) : Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules India Limited Announces FDA Approval for ADHD Treatment
Details : FDA approved Lisdexamfetamine Dimesylate Tablets, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.
Product Name : Vyvanse-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) : Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lisdexamfetamine 70 mg vs Elvanse® 70 mg Bioavailability Under Fasting In Healthy Adults
Details : Lisdexamfetamine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2025
Lead Product(s) : Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
Details : Lisdexamfetamine dimesylate capsules, for oral use is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder and Moderate to Severe Binge Eating Disorder (BED) in adults.
Product Name : Vyvanse-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lisdexamfetamine Dimesylate Capsules are a federally controlled substance (CII) used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and other indications and currently are on the FDA's drug shortage list.
Product Name : Vyvanse-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
